Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Intracellular Contrast Agents' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Intracellular Contrast Agents' found in 1 term [] and 3 definitions []
1 - 4 (of 4)     
Result Pages : [1]
MRI Resources 
Crystallography - MRI Accidents - MRI Centers - Stent - Nerve Stimulator -
 
Intracellular Contrast AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Contrast agent with a preferential intracellular distribution.
Intracellular agents (such as manganese derivatives and ultrasmall superparamagnetic iron oxide), exhibit a flow- and metabolism-dependent uptake. These properties may allow delayed imaging, similar to isotopic methods.
Phospholipid liposomes are rapidly sequestered by the cells in the reticuloendothelial system (RES), primarily in the liver. For imaging of the liver, liposomes may be labeled with MR contrast medium, both positive (T1-shortening) paramagnetic media, and negative (T2-shortening) superparamagnetic media.
Several other nonliposome MR contrast media are also taken up by the RES, e.g.:
Other MR contrast agents accumulate selectively in the hepatocytes, e.g.:
gadoxetic acid (Gd-EOB-DTPA)
spacer
 
• Share the entry 'Intracellular Contrast Agents':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  News & More:
Manganese enhanced MRI provides more accurate details of heart function after a heart attack
Tuesday, 11 May 2021   by www.news-medical.net    
MRI Resources 
Spectroscopy - Collections - Lung Imaging - Process Analysis - Quality Advice - Pathology
 
Liver ImagingForum -
related threadsMRI Resource Directory:
 - Liver Imaging -
 
Liver imaging can be performed with sonography, computed tomography (CT) and magnetic resonance imaging (MRI). Ultrasound is, caused by the easy access, still the first-line imaging method of choice; CT and MRI are applied whenever ultrasound imaging yields vague results. Indications are the characterization of metastases and primary liver tumors e.g., benign lesions such as focal nodular hyperplasia (FNH), adenoma, hemangioma and malignant lesions (cancer) such as hepatocellular carcinomas (HCC). The decision, which medical imaging modality is more suitable, MRI or CT, is dependent on the different factors. CT is less costly and more widely available; modern multislice scanners provide high spatial resolution and short scan times but has the disadvantage of radiation exposure.
With the introduction of high performance MR systems and advanced sequences the image quality of MRI for the liver has gained substantially. Fast spin echo or single shot techniques, often combined with fat suppression, are the most common T2 weighted sequences used in liver MRI procedures. Spoiled gradient echo sequences are used as ideal T1 weighted sequences for evaluating of the liver. The repetition time (TR) can be sufficiently long to acquire enough sections covering the entire liver in one pass, and to provide good signal to noise. The TE should be the shortest in phase echo time (TE), which provides strong T1 weighting, minimizes magnetic susceptibility effects, and permits acquisition within one breath hold to cover the whole liver. A flip angle of 80° provides good T1 weighting and less of power deposition and tissue saturation than a larger flip angle that would provide comparable T1 weighting.
Liver MRI is very dependent on the administration of contrast agents, especially when detection and characterization of focal lesions are the issues. Liver MRI combined with MRCP is useful to evaluate patients with hepatic and biliary disease.
Gadolinium chelates are typical non-specific extracellular agents diffusing rapidly to the extravascular space of tissues being cleared by glomerular filtration at the kidney. These characteristics are somewhat problematic when a large organ with a huge interstitial space like the liver is imaged. These agents provide a small temporal imaging window (seconds), after which they begin to diffuse to the interstitial space not only of healthy liver cells but also of lesions, reducing the contrast gradient necessary for easy lesion detection. Dynamic MRI with multiple phases after i.v. contrast media (Gd chelates), with arterial, portal and late phase images (similar to CT) provides additional information.
An additional advantage of MRI is the availability of liver-specific contrast agents (see also Hepatobiliary Contrast Agents). Gd-EOB-DTPA (gadoxetate disodium, Gadolinium ethoxybenzyl dimeglumine, EOVIST Injection, brand name in other countries is Primovist) is a gadolinium-based MRI contrast agent approved by the FDA for the detection and characterization of known or suspected focal liver lesions.
Gd-EOB-DTPA provides dynamic phases after intravenous injection, similarly to non-specific gadolinium chelates, and distributes into the hepatocytes and bile ducts during the hepatobiliary phase. It has up to 50% hepatobiliary excretion in the normal liver.
Since ferumoxides are not eliminated by the kidney, they possess long plasmatic half-lives, allowing circulation for several minutes in the vascular space. The uptake process is dependent on the total size of the particle being quicker for larger particles with a size of the range of 150 nm (called superparamagnetic iron oxide). The smaller ones, possessing a total particle size in the order of 30 nm, are called ultrasmall superparamagnetic iron oxide particles and they suffer a slower uptake by RES cells. Intracellular contrast agents used in liver MRI are primarily targeted to the normal liver parenchyma and not to pathological cells. Currently, iron oxide based MRI contrast agents are not marketed.
Beyond contrast enhanced MRI, the detection of fatty liver disease and iron overload has clinical significance due to the potential for evolution into cirrhosis and hepatocellular carcinoma. Imaging-based liver fat quantification (see also Dixon) provides noninvasively information about fat metabolism; chemical shift imaging or T2*-weighted imaging allow the quantification of hepatic iron concentration.

See also Abdominal Imaging, Primovistâ„¢, Liver Acquisition with Volume Acquisition (LAVA), T1W High Resolution Isotropic Volume Examination (THRIVE) and Bolus Injection.

For Ultrasound Imaging (USI) see Liver Sonography at Medical-Ultrasound-Imaging.com.
 
Images, Movies, Sliders:
 Anatomic Imaging of the Liver  Open this link in a new window
      

 MRI Liver T2 TSE  Open this link in a new window
    
 
Radiology-tip.comradAbdomen CT,  Biliary Contrast Agents
spacer
Medical-Ultrasound-Imaging.comLiver Sonography,  Vascular Ultrasound Contrast Agents
spacer

• View the DATABASE results for 'Liver Imaging' (13).Open this link in a new window


• View the NEWS results for 'Liver Imaging' (10).Open this link in a new window.
 
Further Reading:
  Basics:
Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests
Thursday, 18 November 2021   by www.nature.com    
Liver Imaging Today
Friday, 1 February 2013   by www.healthcare.siemens.it    
Elastography: A Useful Method in Depicting Liver Hardness
Thursday, 15 April 2010   by www.sciencedaily.com    
Iron overload: accuracy of in-phase and out-of-phase MRI as a quick method to evaluate liver iron load in haematological malignancies and chronic liver disease
Friday, 1 June 2012   by www.ncbi.nlm.nih.gov    
  News & More:
Utility and impact of magnetic resonance elastography in the clinical course and management of chronic liver disease
Saturday, 20 January 2024   by www.nature.com    
Even early forms of liver disease affect heart health, Cedars-Sinai study finds
Thursday, 8 December 2022   by www.eurekalert.org    
For monitoring purposes, AI-aided MRI does what liver biopsy does with less risk, lower cost
Wednesday, 28 September 2022   by radiologybusiness.com    
Perspectum: High Liver Fat (Hepatic Steatosis) Linked to Increased Risk of Hospitalization in COVID-19 Patients With Obesity
Monday, 29 March 2021   by www.businesswire.com    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
T2-Weighted Liver MRI Using the MultiVane Technique at 3T: Comparison with Conventional T2-Weighted MRI
Friday, 16 October 2015   by www.ncbi.nlm.nih.gov    
EORTC study aims to qualify ADC as predictive imaging biomarker in preoperative regimens
Monday, 4 January 2016   by www.eurekalert.org    
MRI effectively measures hemochromatosis iron burden
Saturday, 3 October 2015   by medicalxpress.com    
Total body iron balance: Liver MRI better than biopsy
Sunday, 15 March 2015   by www.eurekalert.org    
MRI Resources 
Calculation - Anatomy - Chemistry - Resources - Hospitals - Functional MRI
 
Molecular Imaging
 
Molecular Imaging is a new diagnostic discipline to visualize biological processes.
Molecular magnetic resonance imaging (mMRI) offers the potential to image tissues at the cellular and subcellular level. Targeted MR contrast agents enhance the diagnostic specificity and range of molecular magnetic resonance imaging.
Other modalities that can be used for noninvasive molecular imaging:
•
Ultrasound;
•
optical imaging;
•
positron emission tomography (PET);
•
single photon emission computed tomography (SPECT).


See also Nanoparticle, Monocrystalline Iron Oxide Nanoparticle, Polycrystalline Iron Oxide Nanoparticles, Liposomes, Monoclonal Antibodies, Bimodal Imaging, Tumor Specific Agents, and Intracellular Contrast Agents.
spacer

• View the DATABASE results for 'Molecular Imaging' (10).Open this link in a new window


• View the NEWS results for 'Molecular Imaging' (28).Open this link in a new window.
 
Further Reading:
  Basics:
Multimodal Nanoparticles for Quantitative Imaging(.pdf)
Tuesday, 13 December 2011   by alexandria.tue.nl    
Molecular Magnetic Resonance Imaging(.pdf)
2005   by www.medical.siemens.com    
  News & More:
Smarter MRI diagnosis with nano MRI lamp
Monday, 6 February 2017   by www.eurekalert.org    
Molecular MRI technique gives early indication of cancer treatment effectiveness
Monday, 11 April 2016   by www.healthimaging.com    
Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Bjorn Wangler
Thursday, 4 February 2016   by www.news-medical.net    
Positron Emission Tomographic Imaging in Stroke
Monday, 28 December 2015   by www.ncbi.nlm.nih.gov    
Potential and Limitations of Oxygen-17 MR Perfusion Measurements
Monday, 1 March 2004   by www.case.edu    
MRI Resources 
Coils - Shoulder MRI - Used and Refurbished MRI Equipment - MRI Accidents - Guidance - Universities
 
Ultrasmall Superparamagnetic Iron OxideInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
(USPIO) The class of the ultrasmall superparamagnetic iron oxide includes several chemically and pharmacologically very distinct materials, which may or may not be interchangeable for a specific use. Some ultrasmall SPIO particles (median diameter less than 50nm) are used as MRI contrast agents (Sinerem®, Combidex®), e.g. to differentiate metastatic from inflammatory lymph nodes. USPIO shows also potential for providing important information about angiogenesis in cancer tumors and could possibly complement MRI helping physicians to identify dangerous arteriosclerosis plaques.
Because of the disadvantageous large T2*//T1 ratio, USPIO compounds are less suitable for arterial bolus contrast enhanced magnetic resonance angiography than gadolinium complexes. The tiny ultrasmall superparamagnetic iron oxides do not accumulate in the RES system as fast as larger particles, which results in a long plasma half-life. USPIO particles, with a small median diameter (less than 10 nm), will accumulate in lymph nodes after an intravenous injection by e.g. direct transcapillary passage through endothelial venules. Once within the nodal parenchyma, phagocytic cells of the mononuclear phagocyte system take up the particles.
As a second way, USPIOs are subsequently taken up from then interstitium by lymphatic vessels and transported to regional lymph nodes. A lymph node with normal phagocytic function takes up a considerable amount and shows a reduction of the signal intensity caused by T2 shortening effects and magnetic susceptibility. Caused by the small uptake of the USPIOs in metastatic lymph nodes, they appear with less signal reduction, and permit the differentiation of healthy lymph nodes from normal-sized, metastatic nodes.

See also Superparamagnetic Contrast Agents, Superparamagnetic Iron Oxide, Very Small Superparamagnetic Iron Oxide Particles, Blood Pool Agents, Intracellular Contrast Agents.
spacer

• View the DATABASE results for 'Ultrasmall Superparamagnetic Iron Oxide' (16).Open this link in a new window


• View the NEWS results for 'Ultrasmall Superparamagnetic Iron Oxide' (2).Open this link in a new window.
 
Further Reading:
  Basics:
Comparison of Two Superparamagnetic Viral-Sized Iron Oxide Particles Ferumoxides and Ferumoxtran-10 with a Gadolinium Chelate in Imaging Intracranial Tumors
2002   by www.ajnr.org    
  News & More:
Optimized Labelling of Human Monocytes with Iron Oxide MR Contrast Agents
Sunday, 30 November 2003   by rsna2003.rsna.org    
10 SUMMARY AND FUTURE PERSPECTIVES
   by dissertations.ub.rug.nl    
MRI Resources 
Portals - General - Online Books - Equipment - Mobile MRI Rental - Spectroscopy
 
     1 - 4 (of 4)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



MRI is trending to low field magnets :
reduced costs will lead to this change 
AI will close the gap to high field 
only in remote areas 
is only temporary 
never 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 29 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]